Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Adverse Events Among Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogs in the United States

Narendranath Epperla, MD, Melissa Pavilack, PharmD, Temitope O Olufade, PhD, Richa Bashyal, Jieni Li, Huseyin Yuce, Leslie Andritsos, MD

Blood (2018) 132 (Supplement 1): 4833.

https://doi.org/10.1182/blood-2018-99-115954

Published: 2018

Journal Articles

Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment

Narendranath Epperla, MDMS, Mirela Anghelina, Qiuhong Zhao, MS, Akwasi Agyeman, James S. Blachly, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Christopher C. Oakes, Michael R. Grever, MD, Leslie Andritsos, MD

Blood (2018) 132 (Supplement 1): 2305.

https://doi.org/10.1182/blood-2018-99-119951

Published: 2018

Journal Articles

Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome

Kerry A. Rogers, MD, Ying Huang, MA, MS, Emily Dotson, PharmD, Jordan Lundberg, PharmD, Leslie Andritsos, MD, Farrukh T. Awan, MD MS, Jeffrey A. Jones, MD MPH, MBA, Jennifer A. Woyach, MD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 5345.

https://doi.org/10.1182/blood.V130.Suppl_1.5345.5345

Published: 2017

Journal Articles

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Blood (2017) 130 (Supplement 1): 4483.

https://doi.org/10.1182/blood.V130.Suppl_1.4483.4483

Published: 2017

Journal Articles

Economic Evaluation for the US of Venetoclax Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Nimer Alsaid, Ali McBride, PharmD,MS, Mok Oh, Daniel Persky, MD, Faiz Anwer, MD, Leslie Andritsos, MD, Abhijeet Kumar, Seongseok Yun, MD PhD, Ivo Abraham, PhD RN

Blood (2017) 130 (Supplement 1): 4678.

https://doi.org/10.1182/blood.V130.Suppl_1.4678.4678

Published: 2017

Journal Articles

Economic Evaluation for the US of Ibrutinib Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Nimer Alsaid, Ali McBride, PharmD,MS, HyunJung Kim, Mok Oh, Leslie Andritsos, MD, Faiz Anwer, MD, Daniel Persky, MD, Abhijeet Kumar, Seongseok Yun, MD PhD, Ivo Abraham, PhD RN

Blood (2017) 130 (Supplement 1): 4679.

https://doi.org/10.1182/blood.V130.Suppl_1.4679.4679

Published: 2017

Journal Articles

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Farrukh T. Awan, MD MS, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Jennifer A. Woyach, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD, Leslie Andritsos, MD, Natarajan Muthusamy, DVM,PhD, Barbara Andersen, PhD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 1748.

https://doi.org/10.1182/blood.V130.Suppl_1.1748.1748

Published: 2017

Journal Articles

Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL

Polina Shindiapina, MD PhD, Soun Khountham, Kerry A. Rogers, MD, Jeffrey Jones, MD MPH, Leslie Andritsos, MD, Kami J. Maddocks, MD, Joseph M. Flynn, DO, MPH, Jennifer A. Woyach, MD, John C. Byrd, MD, Farrukh T. Awan

Blood (2016) 128 (22): 4385.

https://doi.org/10.1182/blood.V128.22.4385.4385

Published: 2016

Journal Articles

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

Jeffrey Jones, MD MPH, Leslie Andritsos, MD, Robert J. Kreitman, MD, Farhad Ravandi, MD, Charles Schiffer, Timothy G. Call, MD, Gerard Lozanski, MD, Pamela Harris, MD, Jennifer Sexton, Amy S Ruppert, MAS, Michael R. Grever

Blood (2016) 128 (22): 1215.

https://doi.org/10.1182/blood.V128.22.1215.1215

Published: 2016

Journal Articles

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

Blood (2016) 128 (22): 1163.

https://doi.org/10.1182/blood.V128.22.1163.1163

Published: 2016

Journal Articles

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

Tracy E Wiczer, PharmD, BCOP, Lauren B Levine, PharmD, BCOP, Jessica Brumbaugh, Jessica Coggins, Qiuhong Zhao, MS, Amy S. Ruppert, MAS, Anli McCoy, PharmD, Kami J. Maddocks, MD, Beth A Christian, MD, Kerry A. Rogers, MD, Leslie Andritsos, MD, Samantha Jaglowski, MD MPH, Steven M Devine, MD, Pierluigi Porcu, MD, Jennifer A. Woyach, MD, Jeffrey Jones, MD MPH, Michael R. Grever, MD, John C. Byrd, MD, Farrukh T. Awan

Blood (2016) 128 (22): 2040.

https://doi.org/10.1182/blood.V128.22.2040.2040

Published: 2016

Journal Articles

Performance of Quick Sepsis-Related Organ Failure Assessment (qSOFA) in Predicting Adverse Outcomes in Acute Leukemia Patients Receiving Induction Chemotherapy

John Vaughn, MD, David Kline, PhD, Nathan Denlinger, DO, Leslie Andritsos, MD, Alison R. Walker, MD MPH

Blood (2016) 128 (22): 2413.

https://doi.org/10.1182/blood.V128.22.2413.2413

Published: 2016

Journal Articles

Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia

Leslie Andritsos, MD, John C. Byrd, MD, Jeffrey A. Jones, MD, MPH, Becker Hewes, MD, Thomas J. Kipps, MD, PhD, Frank J Hsu, Jan A. Burger, MD, PhD

Blood (2010) 116 (21): 2450.

https://doi.org/10.1182/blood.V116.21.2450.2450

Published: 2010

Journal Articles

Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant

Samantha M. Jaglowski, MD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Thomas S. Lin, MD, PhD, Beth Fischer, Diane Scholl, Patrick Elder, MS, Steven M. Devine, MD, Michael R. Grever, M.D., John C. Byrd, MD, Leslie Andritsos, MD

Blood (2010) 116 (21): 2383.

https://doi.org/10.1182/blood.V116.21.2383.2383

Published: 2010

Journal Articles

Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Kristie A. Blum, MD, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Joseph M. Flynn, DO, MPH, Deidre Deam, RN, Nyla A. Heerema, PhD, Mitchell Phelps, PhD, Amy J Johnson, PhD, Michael R. Grever, M.D., John C. Byrd, MD

Blood (2010) 116 (21): 2472.

https://doi.org/10.1182/blood.V116.21.2472.2472

Published: 2010

Journal Articles

Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL

Richard R. Furman, MD, Leslie Andritsos, MD, Ian W. Flinn, MD, PhD, Andres Forero-Torres, MD, Kenneth A. Foon, MD, John M. Pagel, MD, PhD, Anil Singhal, MD, Scott C. Stromatt, MD, John C. Byrd, MD

Blood (2010) 116 (21): 56.

https://doi.org/10.1182/blood.V116.21.56.56

Published: 2010

Journal Articles

Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-δ Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia

Sarah E.M. Herman, Rosa Lapalombella, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Amber L. Gordon, Asha Ramanunni, Brian Lannutti, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2010) 116 (21): 1821.

https://doi.org/10.1182/blood.V116.21.1821.1821

Published: 2010

Journal Articles

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

Mark C Lanasa, MD, PhD, Leslie Andritsos, MD, Jennifer R Brown, MD, PhD, Janice Gabrilove, M.D., Federico Caligaris-Cappio, M.D., Richard Larson, M.D., Thomas J. Kipps, MD, PhD, Veronique Leblond, M.D., Donald Milligan, MD, FRCP, FRCPath, Ann Janssens, M.D., Nyla A. Heerema, Ph.D., Stephan Stilgenbauer, M.D., John C. Byrd, MD, Michael R. Grever, M.D.

Blood (2010) 116 (21): 58.

https://doi.org/10.1182/blood.V116.21.58.58

Published: 2010

Journal Articles

Conditioning with Fludarabine, Busulfan, and ATG Prior to Reduced-Intensity Allogeneic Stem Cell Transplant for CLL Is Associated with a Low Incidence of Acute Graft-Versus-Host Disease.

Samantha M. Jaglowski, MD, Diane Scholl, Patrick Elder, MS, Thomas S. Lin, MD, PhD, John C. Byrd, MD, Steven M. Devine, MD, Leslie Andritsos, MD

Blood (2010) 116 (21): 4568.

https://doi.org/10.1182/blood.V116.21.4568.4568

Published: 2010

Journal Articles

Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol.

Kristie A. Blum, MD, Amy S. Ruppert, Jennifer A. Woyach, MD, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Joseph M. Flynn, DO, MPH, Brad Rovin, MD, Miguel Villalona-Calero, MD, Jia Ji, Mitchell Phelps, PhD, Amy J. Johnson, PhD, Michael R. Grever, M.D., John C. Byrd, MD

Blood (2010) 116 (21): 1386.

https://doi.org/10.1182/blood.V116.21.1386.1386

Published: 2010

NARROW

Adverse Events Among Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogs in the United States

Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment

Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Economic Evaluation for the US of Venetoclax Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

Economic Evaluation for the US of Ibrutinib Versus Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with 17p Deletion

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

Performance of Quick Sepsis-Related Organ Failure Assessment (qSOFA) in Predicting Adverse Outcomes in Acute Leukemia Patients Receiving Induction Chemotherapy

Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia

Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant

Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL

Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-δ Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

Conditioning with Fludarabine, Busulfan, and ATG Prior to Reduced-Intensity Allogeneic Stem Cell Transplant for CLL Is Associated with a Low Incidence of Acute Graft-Versus-Host Disease.

Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only